slides · global inventory
Paragraph
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 118,471
Current window 81,601-81,630
Pages 3,950
Rows per page 30
Component
81,601-81,630 of 118,471
26
The slide uses a combination of narrative argument and a supporting table of pharmacologic approaches to justify the 'difficult' commercial landscape.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
27
The slide uses a comparative analysis of pricing and regulatory status to undermine the competitor's market position.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
28
The slide uses direct quotes from medical professionals to undermine the competitive advantage of the subject drug (Wakix).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
29
The slide uses a scientific diagram to explain the mechanism while simultaneously casting doubt on the underlying theory.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
30
The slide uses a 'villain' narrative style to attack the legitimacy of Harmony Biosciences' IP.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The MonsterLoop · Aha Moment1 hit
31
The slide argues that the patent claims are spurious because the inventors are the same as those who published the molecule in 2002, and PubChem shows prior art from 2006.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
33
The slide uses a 'before-after' style comparison of a website vs. an empty search result to discredit the subject.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
35
The slide uses a narrative of past misconduct to establish a pattern of behavior for the subject.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
40
The slide uses a testimonial quote to support a narrative of corporate malfeasance and trial data manipulation.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
43
The slide uses a Q&A format to present qualitative evidence of internal doubt regarding clinical trial integrity.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
44
The slide uses direct quotes from a neurologist to cast doubt on Bioprojet's professionalism and data management.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
45
The slide uses a bar chart to visualize payment data from CMS OpenPayments to support a narrative of questionable marketing practices.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
46
The slide uses legal filings and OIG reports to establish a pattern of billing abuse in the sleep sector.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
47
The slide uses direct quotes from two different medical professionals to highlight a pattern of disregard for safety protocols.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Struggle1 hit
51
The slide uses a quote from a 2004 NEJM paper to establish a precedent of drug withdrawal, then links the molecular structure (piperidine ring) and receptor activity of pitolisant to these withdrawn drugs.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
52
The slide uses historical news headlines to illustrate the regulatory and safety failure of the drug Seldane.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
53
The slide uses a historical precedent (Seldane/terfenadine recall) to frame the severity of a current drug's (pitolisant) safety profile, highlighting specific death and exposure statistics.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
54
The slide uses a bar chart to compare reporting rates per million daily doses, with specific focus on drugs withdrawn from the market due to cardiac safety concerns.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
55
The slide uses a calculation of daily doses sold based on revenue and price to derive a rate, then compares this against historical data from a Lancet study.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
58
Includes a visual comparison of pharmacophore models and a specific reference to ABT-239.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
60
The slide uses visual evidence to link a specific chemical moiety (piperidine) to a known safety liability (hERG blockade).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The VictoryLoop · The Reveal1 hit
66
The slide uses a 'quote-and-commentary' structure to expose potential corporate malfeasance or negligence.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
68
The slide uses a 'fraud-exposure' narrative, highlighting a specific omission in a scientific paper to imply corporate malfeasance.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller Beat · The Victory1 hit
71
The slide uses a combination of chemical structure diagrams, a tabular summary of clinical trial failures, and a pie chart showing the distribution of indications for failed trials.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
72
The slide highlights BF2.649 (pitolisant) with a red box to emphasize its drug-likeness profile compared to other failed candidates.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
73
The slide uses a 'preempt_rebuttal' strategy by highlighting that even industry giants failed where the current subject company is operating.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
85
The slide uses a Q&A format to build a case against the drug's efficacy based on metabolic pathways.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
86
The slide uses a Q&A format to frame the failure as a known, expected outcome rather than a surprise, highlighting the difficulty of the H3 class.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
88
Uses expert quotes to establish a 'villain' (the drug class/mechanism) and preemptively rebut its efficacy.Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit
89
The slide uses expert testimony to undermine the credibility of the company (Bioprojet) and the drug (pitolisant).Harmony Biosciences (HRMY) · Scorpion Capital
Research note Short seller 1 hit